anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Skin conditions are common in patients on maintenance hemodialysis and those with pancreatitis. However, there is a lack of research on dermatological issues in patients who have both hemodialysis and pancreatitis concurrently.
CASE PRESENTATION: A 62-year-old male patient with a 4-year history of maintenance hemodialysis (MHD) presented with pain and was diagnosed with acute pancreatitis and gallbladder stones. Markedly elevated blood amylase, creatine kinase, and myoglobin were noted, alongside a purplish-red skin discoloration. Treatment included inhibition of digestive fluid secretion, anti-infection measures, blood purification, fasting, rehydration, and symptomatic care. Notably, continuous renal replacement therapy (CRRT) combined with hemoperfusion (HP) was employed. The patient's dialysis effluent initially appeared red. Upon examination of the patient's peripheral blood smear, red blood cell debris was not observed. The dialysis effluent (on Day 0) was analyzed, revealing no hemoglobin (0 g/L) but an elevated myoglobin concentration of 80.4 U/L. After the therapeutic intervention, the indicators, including the blood amylase, C-reactive protein, total bilirubin, creatine kinase, and myoglobin were improved. The patient experienced resolution of sternal and upper abdominal pain within two days. After four consecutive days of CRRT and HP treatment, the skin color returned to normal, alongside improved clarity of the dialysis effluent. Subsequently, the patient's method of blood purification was reverted to conventional hemodialysis. On the eighth day of hospitalization, the patient resumed normal diet and was discharged.
CONCLUSIONS: In the case of the current patient with acute pancreatitis undergoing MHD, it is noteworthy to report the observation of a unique purplish-red skin discoloration. This phenomenon may be attributable to inflammation resulting from acute pancreatitis, and the retention of myoglobin within the body.
PURPOSE:To provide skin with smooth touch, a moist and refreshing feeling after bathing by blending bath salts consisting essentially of a water-soluble inorganic salt with a specific organic silicone compound. CONSTITUTION:100 pts.wt. water-soluble inorganic salt such as sodium chloride, sodium carbonate, boric acid or sodium silicate is blended with 20 pts.wt. organic polysiloxane-polyoxyalkylene copolymer such as copolymer shown by formula I ((a) is 50-2,000; (b) is 10-500; (c) is 2-6; (d) is 3-500; (e) is 0-500; R is H, CH3, C2H5, C3H7, COCH3 or COC2H5), formula II, etc. In blending, both the components may be mixed, dissolved in a solvent such as water or an alcohol, made into a solid without evaporating the solvent and ground into fine powder. The bath salts can be directly used without using a pH adjuster and applicable to any type of water in a bathtub irrespective of soft water and hard water.
The invention discloses a Centella asiatica (L.) Urban medicinal composition for preventing and curing diseases of prostatitis, prostatic hyperplasia and the like. The composition is obtained by extracting from dry herbs or rooted herbs of Centella asiatica (L.) Urban and purifying. The composition is characterized in that the composition comprises asiaticosides, madecassosides, asiaticoside B, quercetin, kaempferol and the like. Pharmacological tests of the composition prove that the composition has the effects of the prevention and the curing of prostatitis, prostatic hyperplasia and the like. The composition has a new use in the preparation of medicines for preventing and curing prostatic diseases. The invention also discloses a medicinal preparation of the composition, which can be anyone of a tablet, a capsule, a pill, a granule, a suspension, a dropping pill, an ointment and a suppository rectal administration preparation.
Talcum powder with a coefficient of friction at least 5% below the coefficient of kinetic friction of Venice talc 00000 is prepared by coating talc with 0.3-1.5% of a silicone (pref. dimethyl polysiloxane) pref. of viscosity 10cS at 25 degrees C. Pref. alcohol free perfume comprises 0.05-1.5 wt.% of the talc. Coating is performed by praying and mixing to achieve uniform coverage. The powder is very soft and is hydrophobic and imparts softness to skin.
BACKGROUND: It is plausible that supplementation with specific amino acids or metabolites could attenuate skeletal muscle wasting during critical illness. The aim of this systematic review was to explore if amino acids or their derivatives impact skeletal muscle wastage in critically ill adults.
METHODS: Four databases were systematically searched to identify randomised control trials which delivered enteral supplemental amino acids, or their metabolites compared with placebo, standard care or no intervention, to critically ill patients and reported outcomes of skeletal muscle mass, plasma amino acids, nitrogen balance, or muscle strength. Two authors independently completed screening, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2 Tool. A meta-analysis was planned but heterogeneity in the type of intervention used and outcome assessment precluded this. Therefore, data were synthesised using vote counting.
RESULTS: Thirty randomised control trials, comprising 1976 patients were included. The most frequently studied interventional amino acid or metabolite was glutamine (n = 12 trials), a combination (n = 9), arginine (n = 6), β-hydroxy β-methylbutyrate (HMB) (n = 2) or ornithine (n = 1). Six trials (including 284 participants) measured skeletal muscle following supplementation, four of which used HMB alone or in combination as the intervention. Of these, one trial observed an attenuation of muscle wasting with a combination of amino acids, one observed an exacerbation of muscle wasting with HMB, three trials observed no impact on muscle wasting with HMB or a combination of amino acids and one trial reported no information.
CONCLUSION: Six trials have investigated the effect of enteral amino acid or amino acid metabolite supplementation on muscle mass in critically ill. Heterogeneity of interventions, outcome assessments and direction of effects limits the certainty regarding the effect of supplemental amino acids, or their metabolites, on skeletal muscle wasting during critical illness. The trial protocol is registered on PROSPERO (CRD42021275989).
Participants randomized to control will not receive the APOL1 genetic test upon study enrollment. They will be offered the option to take the test during their final follow-up study visit (12 months post enrollment).
The treatment included a comprehensive therapy: redon-sulfide baths, partial mud baths, kinesiotherapy, terrain therapy, dry massage, laser therapy, low-frequency magnetic field, ultrasonotherapy, cryotherapy, electrotherapy, light therapy. On the day of admission to the SPA the patients were subjected to subjective and objective examination. Laboratory tests (lipids profile, CRP, smear blood morphology, TAS- total antioxidative potential, the concentration of endorphins and serotonin, bilirubin, uric acid, albumin) were performed before treatment on day 5 and after 18 days. In addition, before and after treatment, standard scales were used to assess pain intensity: VAS scale and anxiety and depression levels - HADS scale.
Teratogenic Effects

Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Pregnancy Category C
PURPOSE:To provide a hepatic function improving medicine having both anti- inflammatory and anti-fibrogenetic activity, effective for both acute and chronic hepatopathy, containing, as an active ingredient, lithospermic acid B isolated from the extract of roots of Schinopsis lerentzii or a pharmaceutically permissible salt thereof. CONSTITUTION:The medicine containing, as an active ingredient, lithospermic acid B of formula I separated and purified from the extract of roots of Schinopsis lerentzii or a pharmaceutically permissible salt thereof [esp. a salt of formula II (M is Mg, 2K, 2NH4 or Ca). This medicine have such activities as to suppress 5-lipoxinase activity in the liver to inhibit leukotriene synthesis, and suppress the production decline in prostaglandin from leukocytes with hepatic infiltration. This medicine can be used in the form of an oral agent formulated with a vehicle (e.g. power, granules, tablets, sugar-coated tablets, or capsules). Also, the lithospermic acid B salt is readily soluble in water, therefore, being usable as an injection.
BACKGROUND: The association between TCF7L2 and CAPN10 gene polymorphisms and gestational diabetes mellitus (GDM) has been explored in diverse populations across different geographical regions. Yet, most of these studies have been confined to a limited number of loci, resulting in inconsistent findings. In this study, we conducted a comprehensive review of published literature to identify studies examining the relationship between TCF7L2 and CAPN10 gene polymorphisms and the incidence of GDM in various populations. We specifically focused on five loci that were extensively reported in a large number of publications and performed a meta-analysis.
METHODS: We prioritized the selection of SNPs with well-documented correlations established in existing literature on GDM. We searched eight Chinese and English databases: Cochrane, Elton B. Stephens. Company (EBSCO), Embase, Scopus, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and China Science and Technology Journal Database and retrieved all relevant articles published between the inception of the database and July 2022. The Newcastle Ottawa Scale (NOS) was used to evaluate the selected articles, and the odds ratio (OR) was used as the combined effect size index to determine the association between genotypes, alleles, and GDM using different genetic models. Heterogeneity between the studies was quantified and the I2 value calculated. Due to large heterogeneities between different ethnic groups, subgroup analysis was used to explore the correlation between genetic polymorphisms and the incidence of GDM in the different populations. The stability of the results was assessed using sensitivity analysis. Begg's and Egger's tests were used to assess publication bias.
RESULTS: A total of 39 articles reporting data on 8,795 cases and 16,290 controls were included in the analysis. The frequency of the rs7901695 genotype was statistically significant between cases and controls in the European population (OR = 0.72, 95% CI: 0.65-0.86) and the American population (OR = 0.61, 95% CI: 0.48-0.77). The frequencies of rs12255372, rs7901695, rs290487, and rs2975760 alleles were also considerably different between the cases and controls in the populations analyzed.
CONCLUSIONS: rs7903146, rs12255372, rs7901695, rs290487, and rs2975760 were associated with the incidence of GDM in different populations.
Dysfunction in the mesocortical pathway, connecting the ventral tegmental area (VTA) to the prefrontal cortex, has been implicated in chronic pain. While extensive research has focused on the role of dopamine, the contribution of glutamatergic signaling in pain modulation remains unknown. Using in vivo calcium imaging, we observe diminished VTA glutamatergic activity targeting the prelimbic cortex (PL) in a mouse model of neuropathic pain. Optogenetic activation of VTA glutamatergic terminals in the PL alleviates neuropathic pain, whereas inhibiting these terminals in naïve mice induces pain-like responses. Importantly, this pain-modulating effect is independent of dopamine co-release, as demonstrated by CRISPR/Cas9-mediated gene deletion. Furthermore, we show that VTA neurons primarily project to excitatory neurons in the PL, and their activation restores PL outputs to the anterior cingulate cortex, a key region involved in pain processing. These findings reveal a distinct mesocortical glutamatergic pathway that critically modulates neuropathic pain independent of dopamine signaling.
An N-substituted imidazole carboxylate chiral compound containing an ether side chain, a preparation method and application thereof. The structure of the compound is shown as a formula . The compound can produce a rapid and reversible general anesthesia effect. Animal experiments show that the compound has the pharmacological characteristics of rapidness and short effect, can be used as a quick-acting and short-acting general anesthetic, can reduce the inhibition on the synthesis of adrenocortical hormone compared with etomidate, is quick and thorough in revival and recovery, and has obvious advantages and good application prospect. The only chiral carbon in the structure of the compound must be of the R type. The imidazole ring in the structure of the compound has an acidifiable N atom, so the compound and the medicinal salt molecules thereof can be applied to the preparation of central inhibitory medicaments for producing sedative hypnotic and/or anesthetic effects on animals or human beings through intravenous or intravenous routes. （Ⅰ）
<P>PROBLEM TO BE SOLVED: To provide a cosmetic which can simply remove keratotic plug incapable of being removed with ordinary cleansing cosmetics.  <P>SOLUTION: This cleansing cosmetic is characterized by containing (1) a dibasic acid di(2 to 5C) ester and (2) an N-acyl sarcosine or its ester. The acyl group in the N-acyl sarcosine or its ester is preferably a 10 to 24C acyl group. It is preferable that the cleansing cosmetic is a cosmetic aiming the removal of keratotic plugs. In addition, it is preferable to contain a carbonic diester.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The invention relates to a method for checking and accepting traditional Chinese medicine donkey-hide gelatin raw material medicine donkey skin. The method is suitable for the special process of weighing, checking and accepting raw material medicine donkey skin in donkey-hide gelatin industry. The method comprises the following steps: (1) washing; (2) removing meat; (3) washing the skin by using edible alkaline water; (4) washing the skin by using edible saline water; (5) centrifuging for draining; (6) weighing and pricing. According to the process, the quality consistency of the checked and weighed donkey skin is effectively ensured through mechanical meat removal and skin washing through edible alkaline water and edible saline water. In the mechanical meat removal process, excessive grease is removed, and the problem that the grease thickness of the skin is not uniform is solved; in the process of washing the skin by using edible alkaline water, sediments on the skin are effectively washed due to the saponification obtained by reacting edible alkali and the grease, and sediment adulteration is eliminated; in the process of washing the skin by using edible saline water, water of the skin is lost by soaking the skin by using high-concentration saline water, and the water filling degree of the skin is consistent in the saline water of fixed concentration. According to the processes, same-quality same-price check and acceptance of various styles of donkey skins such as wet salted hides, fresh hides, fresh hide frozen packages, dry salted hides, semi-dry hides and slightly dried hides are effectively finished, and various influences of adulteration and non-uniform quality are eliminated.
Patients with acute lymphoblastic leukemia receive alisertib PO QD on days 1-7. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.
An example embodiment includes a method of employee activity and performance tracking. The method includes receiving data packets from a base station. The data packets include locational information pertaining to one or more employees. The method also includes calculating an event timeframe from the data packets. The event timeframe includes a start date/time of an event, an end date/time of the event, a location of the event, and an identification of one or more employees involved in the event. The method further includes refining the event timeframe and communicating the event timeframe to the one or more employees identified in the event timeframe. The method also includes receiving a designation by the one or more employees, the designation including details of the event. The method further includes storing the data packets, the event timeframe, and the designation.
Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
The present invention provides a stabilization method, a preservation method and the like method of reduced coenzyme Q10, which is useful as functional nutritive foods, specific health foods and the like. Furthermore, the present invention provides a method for efficiently obtaining reduced coenzyme Q10 of high quality and by a method suitable for a commercial production. <??>It is possible to handle and stably preserve reduced coenzyme Q10 under a condition that oxidation by a molecular oxygen is inhibited by contacting reduced coenzyme Q10 with an ascorbic acid and citric acid or a related compound thereof, and thus a stabilized composition is obtained. Moreover, reduced coenzyme Q10 is converted into a crystalline state in such a condition that the formation of oxidized coenzyme Q10 as a byproduct is minimized by crystallizing reduced coenzyme Q10 in the presence of ascorbic acid or a related compound thereof, etc., and thus a reduced coenzyme Q10 crystal of high quality is produced. Furthermore, by successively crystallizing the generated reduced coenzyme Q10 in the presence of ascorbic acid or a related compound thereof after reducing oxidized coenzyme Q10 to reduced coenzyme Q10 using ascorbic acid or a related compound thereof, operations are simplified and minimized, and thus reduced coenzyme Q10 of high quality is produced.
Consider reducing digoxin dose when verapamil and digoxin are to be given together. Monitor digoxin level periodically during therapy. Chronic verapamil treatment can increase serum digoxin levels by 50% to 75% during the first week of therapy, and this can result in digitalis toxicity. In patients with hepatic cirrhosis the influence of verapamil on digoxin pharmacokinetics is magnified. Verapamil may reduce total body clearance and extrarenal clearance of digoxin by 27% and 29%, respectively. If digoxin toxicity is suspected, suspend or discontinue digoxin therapy.

In previous clinical trials with other verapamil formulations related to the control of ventricular response in patients taking digoxin who had atrial fibrillation or atrial flutter, ventricular rates below 50/min at rest occurred in 15% of patients, and asymptomatic hypotension occurred in 5% of patients.
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to endocrinology, and deals with treatment of diabetes mellitus, complicated by accompanying diseases, in particular, by parasite invasions. For this purpose electro-activated water solutions of inorganic salts are introduced at the background of antihyperglycemic medications. On first 5 days solution of anolyte (EWS-A) with redox potential (RP) from +700 to +800 mV and with pH from 6.0 to 4.5, after which for 5 days introduced is catholyte solution (EWS-C) with RP from -400 to -600 mV and pH from 9.5 to 10.5; then for 10 days introduced are heated to +36°C - +37°C EWS-C and EWS-A are introduced with their alternation for 24 hours. In case of accompanying parasite invasion, EWS-A in combination with anti-parasitic vegetable medications in form of rectal microclysters for first 5 days of treatment is additionally introduced for first 5 days of treatment. EWS-C in combination with rectal microclysters with probiotic additives is introduced for the following 10 days. In case of detection of Opisthorchida, biltricide is introduced on the 15-th day in dose 75 mg/kg, and duodenal probing with anti-parasitic medication is carried out on the 16-th day. Starting with the 6-th day and to the completion of treatment (21-st day) fermented milk product "Narine" is administered in dose 1 tablespoon 3 times per day 30-40 minutes before meal.EFFECT: mode of introducing electro-activated water solutions in complex with probiotics and anti-parasitic preparations provides efficient treatment of parasite invasions in combination with gradual normalisation of carbohydrate and lipid exchange in patients with diabetes mellitus.2 cl, 2 ex, 4 tbl
The safety and pharmacokinetics of TORISEL were evaluated in a dose escalation phase 1 study in 110 patients with normal or varying degrees of hepatic impairment. Patients with baseline bilirubin >1.5×ULN experienced greater toxicity than patients with baseline bilirubin ≤1.5×ULN when treated with TORISEL. The overall frequency of ≥ grade 3 adverse reactions and deaths, including deaths due to progressive disease, were greater in patients with baseline bilirubin >1.5×ULN due to increased risk of death [see Contraindications (4)].

Use caution when treating patients with mild hepatic impairment. Concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated AST or bilirubin levels. If TORISEL must be given in patients with mild hepatic impairment (bilirubin >1 – 1.5×ULN or AST >ULN but bilirubin ≤ULN), reduce the dose of TORISEL to 15 mg/week [see Dosage and Administration (2.4)].
Encapsulated or embedded medicaments are produced by (a) dissolving a hydrophobic wall matl. (pref. a non-toxic synthetic high-mol. polymer) in >=1 water-immiscible org. solvent having a b.pt. is not >100 degrees C, a vapour pressure greater than that of water and a dielectric constant is not >10, (b) dissolving or dispersing in the resulting soln. a medicament which is water-insol. or has a low solubility in water, (c) dispersing the resulting soln. or dispersion in a carrier (pref. an aq. hydrophilic colloid and/or an aq. anionic surfactant) so as to form fine droplets, and (d) evapg. the org. solvent. The process gives microcapsules under mild conditions so that the medicament is not decomposed. The microcapsules give excellent masking of unpleasant flavours and odours and improve the stability of the medicament. The microcapsules are so fine that they can be treated as dust-fine powders, and individual microcapsules contain practically identical amts. of medicament, making them partic. suitable for medicinal use.